Company intelligence / Profile preview

成都世联康健

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

成都世联康健生物科技有限公司（简称世联康健）成立于2018年，是一家专注于干细胞药物研发与临床转化的国家高新技术企业。公司由华西医院、华西口腔医院、华西第二医院及田卫东教授团队共同注资成立，依托华西医学资源，构建了细胞产业一站式全链条创新平台。世联康健自主研发的人牙囊间充质干细胞注射液(SLDSC001)于2025年正式获批IND并启动临床I期试验，用于治疗牙周炎，是四川省首个获批IND的干细胞药物。此外，公司还拥有四川省细胞库、符合GMP标准的区域细胞制备中心以及天府细胞质量检测与评价中心，能够提供细胞技术和细胞药物转化的CDMO及中试服务。

Therapeutic areas: Infectious Diseases
Modalities: Cell therapyBiologic
Industry: Biotech

Partnerships

四川大学华西口腔医院北京大学口腔医院川投大健康产业集团

Beyond the preview

Go deeper on 成都世联康健.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 成都世联康健.

Explore the full profile